Chinese biotech Ascletis rallies in HK debut, in test of new market rules

HONG KONG: Shares in Chinese biotech company Ascletis Pharma Inc rose as much as 6.4 percent on their debut in Hong Kong on Wednesday, in the first such listing in the city under new rules designed to attract drug developers.

The initial public offering (IPO) is seen as a test of the new regime as Hong Kong seeks to establish itself as a financing centre for the growing number of Chinese biotechs. A successful float by Ascletis is thought likely to encourage fellow biotechs to pursue a listing.

The rules are part of the city’s efforts to better compete against New York, its arch rival, for listings. Currently the U.S. is the biggest centre for biotech IPOs, with $2.4 billion worth of such shares sold last year.

Ascletis shares rose as high as HK$14.9 as trading got underway, compared with the IPO price of HK$14. However they eased to HK$14 after the first hour of trade in a flat market.

Ascletis last month priced its deal at the middle of a HK$12 to HK$16 range, valuing the biotech firm at $2 billion.

Under rules in place since April 30, biotech firms without revenue or profit can apply to list in Hong Kong.

More than 10 companies – mostly Chinese and including Innovent Biologics and Shanghai Henlius Biotech – plan to list in Hong Kong and some have dropped U.S. IPO plans in favour of listing closer to home.

Ascletis sold 224 million new shares, or 20 percent of its enlarged share capital, in the IPO.

Responding to questions about China’s recent vaccine scandal, where a pharmaceutical company was found to have made and distributed poor quality vaccines, Ascletis founder Wu Jinzi said quality was “the lifeline” of his company.

“We are going to make the best quality, most effective and the safest drugs for patients in China and the world,” Wu said at the listing ceremony at the Hong Kong exchange.

Hangzhou-based Ascletis, founded in 2013, has two hepatitis C virus drug candidates at or near commercial stage and one HIV drug that has completed a phase IIa clinical trial. It also has a liver cancer drug candidate that has completed phase I and phase I extension clinical trials.

China Merchants Securities, Goldman Sachs and Morgan Stanley led the deal.

The biggest biotech IPO in Hong Kong – under previous rules which required certain levels of either profitability or cashflow – was that of state-backed China Resources Pharmaceutical Group Ltd which raised $1.9 billion in 2016.

(Reporting by Julia Fioretti and Kane Wu; Editing by Christopher Cushing and Stephen Coates)

  • Related Posts

    • Pharma
    • March 27, 2024
    • 98 views
    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Haryana has blacklisted Maiden Pharmaceuticals Ltd, based at Sonepat, for three years, thereby debarring the firm from participating in state tenders. All rate contracts issued to the firm have also…

    • Pharma
    • March 27, 2024
    • 67 views
    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    New Delhi: The Drugs Consultative Committee (DCC), the advisory committee formed by the Central government to advise the Central and state governments on matters that require uniform implementation of drug laws…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Lee Health develops natural capsule for effective Heart care

    Lee Health develops natural capsule for effective Heart care

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down